Quick Answer
Viking Therapeutics, Inc. reported Operating Income of -$393.34 million for fiscal year 2025.
Viking Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$393.34M | -160.6% |
| 2024 | -$150.92M | -49.7% |
| 2023 | -$100.83M | -43.3% |
| 2022 | -$70.36M | -26.4% |
| 2021 | -$55.68M | -30.5% |
| 2020 | -$42.66M | -30.5% |
| 2019 | -$32.69M | -24.9% |
| 2018 | -$26.16M | -37.2% |
| 2017 | -$19.07M | -37.7% |
| 2016 | -$13.85M | -15.4% |
| 2015 | -$12.00M | +48.9% |
| 2014 | -$23.47M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$98.56M | -169.6% | -32.2% |
| June 30, 2025 | -$74.57M | -119.0% | -34.4% |
| March 31, 2025 | -$55.47M | -62.8% | -51.7% |
| September 30, 2024 | -$36.56M | -34.1% | -7.3% |
| June 30, 2024 | -$34.05M | -43.4% | +0.1% |
| March 31, 2024 | -$34.07M | -65.9% | -25.0% |
| September 30, 2023 | -$27.27M | -68.3% | -14.8% |
| June 30, 2023 | -$23.74M | -34.6% | -15.6% |
- Viking Therapeutics, Inc. showed a decrease of -160.6% in Operating Income compared to the prior fiscal year.
- Over the 2014–2025 period, Viking Therapeutics, Inc.’s operating income has declined by 1576.1% (from -$23.47 million to -$393.34 million).
- The most recent figure is from Viking Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: